In BC, PD-L1 is more expressed in stromal immune cells (ICs) compared to tumor epithelium and is commonly associated with unfavorable clinicopathologic features (i.e., a large tumor size and poorly differentiated histological grade, high Ki67), high TIL counts, TNBC subtype and HER2+ status [22]. This evidence concerns the gene ERBB2 and breast cancer.